# Verrica Pharmaceuticals Inc.: financial statements, quarterly

VRCA · Nasdaq · CIK 1660334 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vrca.md) · [Financials](/companies/vrca/financials.md) · [Filings](/companies/vrca/filings.md) · [Insiders](/companies/vrca/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vrca/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.9](/filings/0000950170-24-120982.md) | [2.0 d](/filings/0000950170-25-037172.md) | [3.8](/filings/0000950170-25-070452.md) | [5.2](/filings/0000950170-25-107358.md) | [(1.8)](/filings/0000950170-24-120982.md) | [0.3 d](/filings/0000950170-25-037172.md) | [3.4](/filings/0000950170-25-070452.md) | [12.7](/filings/0000950170-25-107358.md) | [14.3](/filings/0001660334-25-000006.md) | [5.1 d](/filings/0001660334-26-000008.md) | [5.0](/filings/0001660334-26-000014.md) | [5.9](/filings/0001660334-26-000025.md) |
| Cost of revenue | $m | [0.3](/filings/0000950170-23-061543.md) | [0.2 d](/filings/0000950170-25-037172.md) | [0.7](/filings/0000950170-24-058208.md) | [0.7](/filings/0000950170-24-096669.md) | [0.4](/filings/0000950170-24-120982.md) | [0.8 d](/filings/0000950170-25-037172.md) | [0.7](/filings/0000950170-25-070452.md) | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [6.5](/filings/0000950170-24-120982.md) | [5.3 d](/filings/0000950170-25-037172.md) | [4.9](/filings/0000950170-25-070452.md) | [3.3](/filings/0000950170-25-107358.md) | [2.4](/filings/0001660334-25-000006.md) | [1.2 d](/filings/0001660334-26-000008.md) | [2.3](/filings/0001660334-26-000014.md) | [1.8](/filings/0001660334-26-000025.md) | [2.2](/filings/0001660334-25-000006.md) | [2.5 d](/filings/0001660334-26-000008.md) | [3.9](/filings/0001660334-26-000014.md) | [6.0](/filings/0001660334-26-000025.md) |
| Selling, general and administrative | $m | [20.1](/filings/0000950170-24-120982.md) | [17.0 d](/filings/0000950170-25-037172.md) | [16.3](/filings/0000950170-25-070452.md) | [16.5](/filings/0000950170-25-107358.md) | [16.1](/filings/0001660334-25-000006.md) | [9.9 d](/filings/0001660334-26-000008.md) | [8.8](/filings/0001660334-26-000014.md) | [8.9](/filings/0001660334-26-000025.md) | [9.4](/filings/0001660334-25-000006.md) | [8.1 d](/filings/0001660334-26-000008.md) | [10.0](/filings/0001660334-26-000014.md) | [10.3](/filings/0001660334-26-000025.md) |
| Operating income | $m | [(23.9)](/filings/0000950170-24-120982.md) | [(23.1) d](/filings/0000950170-25-037172.md) | [(18.6)](/filings/0000950170-25-070452.md) | [(15.2)](/filings/0000950170-25-107358.md) | [(20.7)](/filings/0001660334-25-000006.md) | [(11.4) d](/filings/0001660334-26-000008.md) | [(8.1)](/filings/0001660334-26-000014.md) | [1.5](/filings/0001660334-26-000025.md) | [1.6](/filings/0001660334-25-000006.md) | [(7.2) d](/filings/0001660334-26-000008.md) | [(9.7)](/filings/0001660334-26-000014.md) | [(13.1)](/filings/0001660334-26-000025.md) |
| Interest expense | $m | [1.7](/filings/0000950170-23-061543.md) | [2.3 d](/filings/0000950170-24-022659.md) | [2.3](/filings/0000950170-24-058208.md) | [2.4](/filings/0000950170-24-096669.md) | [2.4](/filings/0001660334-25-000006.md) | [2.3 d](/filings/0001660334-26-000008.md) | [2.2](/filings/0001660334-26-000014.md) | [2.1](/filings/0001660334-26-000025.md) | [2.1](/filings/0001660334-25-000006.md) | [1.3 d](/filings/0001660334-26-000008.md) | [0.2](/filings/0001660334-26-000014.md) | [0.2](/filings/0001660334-26-000025.md) |
| Net income | $m | [(24.8)](/filings/0000950170-24-120982.md) | [(24.6) d](/filings/0000950170-25-037172.md) | [(20.3)](/filings/0001660334-25-000006.md) | [(17.2)](/filings/0001660334-25-000006.md) | [(22.9)](/filings/0001660334-25-000006.md) | [(16.2) d](/filings/0001660334-26-000008.md) | [(9.7)](/filings/0001660334-26-000025.md) | [0.2](/filings/0001660334-26-000025.md) | [(0.3)](/filings/0001660334-25-000006.md) | [(8.1) d](/filings/0001660334-26-000008.md) | [(9.7)](/filings/0001660334-26-000025.md) | [(13.2)](/filings/0001660334-26-000025.md) |
| Diluted EPS | $ per share | [(0.54)](/filings/0000950170-24-120982.md) | not reported | [(0.44)](/filings/0000950170-25-070452.md) | [(3.70)](/filings/0000950170-25-107358.md) | [(4.88)](/filings/0001660334-25-000006.md) | not reported | [(1.03)](/filings/0001660334-26-000014.md) | [0.02](/filings/0001660334-26-000025.md) | [(0.03)](/filings/0001660334-25-000006.md) | not reported | [(0.45)](/filings/0001660334-26-000014.md) | [(0.62)](/filings/0001660334-26-000025.md) |
| Basic EPS | $ per share | [(0.54)](/filings/0000950170-24-120982.md) | not reported | [(0.44)](/filings/0000950170-25-070452.md) | [(3.70)](/filings/0000950170-25-107358.md) | [(4.88)](/filings/0001660334-25-000006.md) | not reported | [(1.03)](/filings/0001660334-26-000014.md) | [0.02](/filings/0001660334-26-000025.md) | [(0.03)](/filings/0001660334-25-000006.md) | not reported | [(0.45)](/filings/0001660334-26-000014.md) | [(0.62)](/filings/0001660334-26-000025.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [84.3](/filings/0000950170-23-061543.md) | [69.5](/filings/0000950170-25-037172.md) | [48.9](/filings/0000950170-24-058208.md) | [31.9](/filings/0000950170-24-096669.md) | [23.0](/filings/0000950170-24-120982.md) | [46.3](/filings/0001660334-26-000008.md) | [29.6](/filings/0001660334-26-000014.md) | [15.4](/filings/0001660334-26-000025.md) | [21.1](/filings/0001660334-25-000006.md) | [30.1](/filings/0001660334-26-000025.md) | [20.6](/filings/0001660334-26-000014.md) | [11.2](/filings/0001660334-26-000025.md) |
| Current assets | $m | [91.7](/filings/0000950170-23-061543.md) | [77.5](/filings/0000950170-25-037172.md) | [61.4](/filings/0000950170-24-058208.md) | [47.3](/filings/0000950170-24-096669.md) | [28.2](/filings/0000950170-24-120982.md) | [51.2](/filings/0001660334-26-000008.md) | [39.5](/filings/0000950170-25-070452.md) | [36.8](/filings/0000950170-25-107358.md) | [36.3](/filings/0001660334-25-000006.md) | [42.5](/filings/0001660334-26-000025.md) | [34.1](/filings/0001660334-26-000014.md) | [32.6](/filings/0001660334-26-000025.md) |
| Total assets | $m | [97.1](/filings/0000950170-23-061543.md) | [81.6](/filings/0000950170-25-037172.md) | [66.3](/filings/0000950170-24-058208.md) | [52.0](/filings/0000950170-24-096669.md) | [32.9](/filings/0000950170-24-120982.md) | [54.1](/filings/0001660334-26-000008.md) | [42.2](/filings/0000950170-25-070452.md) | [39.1](/filings/0000950170-25-107358.md) | [40.9](/filings/0001660334-25-000006.md) | [47.1](/filings/0001660334-26-000025.md) | [38.8](/filings/0001660334-26-000014.md) | [36.0](/filings/0001660334-26-000025.md) |
| Current liabilities | $m | [11.4](/filings/0000950170-23-061543.md) | [17.0](/filings/0000950170-25-037172.md) | [19.4](/filings/0000950170-24-058208.md) | [20.1](/filings/0000950170-24-096669.md) | [21.0](/filings/0000950170-24-120982.md) | [29.0](/filings/0001660334-26-000008.md) | [29.4](/filings/0000950170-25-070452.md) | [29.2](/filings/0000950170-25-107358.md) | [28.9](/filings/0001660334-25-000006.md) | [16.4](/filings/0001660334-26-000025.md) | [16.2](/filings/0001660334-26-000014.md) | [22.4](/filings/0001660334-26-000025.md) |
| Total liabilities | $m | [54.8](/filings/0000950170-23-061543.md) | [61.8](/filings/0000950170-25-037172.md) | [64.8](/filings/0000950170-24-058208.md) | [65.3](/filings/0000950170-24-096669.md) | [67.0](/filings/0000950170-24-120982.md) | [64.0](/filings/0001660334-26-000008.md) | [60.8](/filings/0000950170-25-070452.md) | [56.6](/filings/0000950170-25-107358.md) | [57.9](/filings/0001660334-25-000006.md) | [22.4](/filings/0001660334-26-000025.md) | [22.7](/filings/0001660334-26-000014.md) | [31.7](/filings/0001660334-26-000025.md) |
| Long-term debt | $m | [42.4](/filings/0000950170-23-061543.md) | [42.9](/filings/0000950170-25-037172.md) | [42.8](/filings/0000950170-24-058208.md) | [42.8](/filings/0000950170-24-096669.md) | [43.3](/filings/0000950170-24-120982.md) | [31.0](/filings/0001660334-26-000008.md) | [27.8](/filings/0000950170-25-070452.md) | [24.6](/filings/0000950170-25-107358.md) | [21.6](/filings/0001660334-25-000006.md) | [0.0](/filings/0001660334-26-000008.md) | not reported | not reported |
| Current portion of debt | $m | not reported | [0.0](/filings/0000950170-25-037172.md) | not reported | not reported | not reported | [12.9](/filings/0001660334-26-000008.md) | [12.8](/filings/0000950170-25-070452.md) | [12.7](/filings/0000950170-25-107358.md) | [12.5](/filings/0001660334-25-000006.md) | [0.0](/filings/0001660334-26-000008.md) | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [42.3](/filings/0000950170-24-120982.md) | [19.8](/filings/0001660334-26-000008.md) | [1.5](/filings/0001660334-25-000006.md) | [(13.3)](/filings/0001660334-25-000006.md) | [(34.1)](/filings/0001660334-25-000006.md) | [(9.9)](/filings/0001660334-26-000025.md) | [(18.6)](/filings/0001660334-26-000025.md) | [(17.5)](/filings/0001660334-26-000025.md) | [(17.0)](/filings/0001660334-25-000006.md) | [24.7](/filings/0001660334-26-000025.md) | [16.1](/filings/0001660334-26-000025.md) | [4.3](/filings/0001660334-26-000025.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(14.8) d](/filings/0000950170-24-120982.md) | [(14.5) d](/filings/0000950170-25-037172.md) | [(19.9)](/filings/0000950170-25-070452.md) | [(16.4) d](/filings/0000950170-25-107358.md) | [(8.6) d](/filings/0001660334-25-000006.md) | [(16.1) d](/filings/0001660334-26-000008.md) | [(12.7)](/filings/0001660334-26-000014.md) | [(10.0) d](/filings/0001660334-26-000025.md) | [9.7 d](/filings/0001660334-25-000006.md) | [(4.6) d](/filings/0001660334-26-000008.md) | [(9.2)](/filings/0001660334-26-000014.md) | [(9.3) d](/filings/0001660334-26-000025.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-120982.md) | [0.2 d](/filings/0000950170-25-037172.md) | [0.0](/filings/0000950170-24-058208.md) | [0.0 d](/filings/0000950170-25-107358.md) | [0.0 d](/filings/0001660334-25-000006.md) | [0.0 d](/filings/0001660334-26-000008.md) | not reported | not reported | [0.0 d](/filings/0001660334-25-000006.md) | [0.0 d](/filings/0001660334-26-000008.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.3](/filings/0000950170-23-061543.md) | [43.0](/filings/0000950170-24-058208.md) | [45.9](/filings/0000950170-24-096669.md) | [46.1](/filings/0000950170-24-120982.md) | [46.5](/filings/0000950170-25-070452.md) | [4.7](/filings/0000950170-25-107358.md) | [4.7](/filings/0001660334-25-000006.md) | [9.5](/filings/0001660334-26-000014.md) | [9.5](/filings/0001660334-26-000025.md) | [9.5](/filings/0001660334-25-000006.md) | [21.3](/filings/0001660334-26-000014.md) | [21.3](/filings/0001660334-26-000025.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 17,178,786 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001660334-26-000025.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.